THE FOLLOWING RANDOMIZED, DOUBLE-MASKED CLINICAL TRIALS WERE CONDUCTED FOR THE 5 LUCENTIS INDICATIONS:

wAMD: MARINA—Phase III, multicenter, 2-year, sham injection–controlled study; primary end point at 1 year. ANCHOR—Phase III, multicenter, 2-year, active treatment–controlled study; primary end point at 1 year. PIER—Phase IIIb, 2-year, sham injection–controlled study; primary end point at 1 year. HARBOR—Phase III, multicenter, 2-year, active treatment–controlled dose-response study; primary end point at 1 year. DR and DME: RISE and RIDE—Methodologically identical, Phase III, multicenter, 3-year, sham injection–controlled studies; primary end point at 2 years. Protocol S—Phase III, multicenter, 2-year, active-controlled study; key clinical outcomes at 2 years. mCNV: RADIANCE—Phase III, multicenter, 1-year, active-controlled study; key clinical outcomes at month 3. RVO: BRAVO—Phase III, multicenter, 1-year, sham injection–controlled study; primary end point at 6 months. CRUISE—Phase III, multicenter, 1-year, sham injection–controlled study; primary end point at 6 months.2-7,9,11,14

Resources
Resources for your patients.
LUCENTIS Direct
Simple, personalized ordering.
LUCENTIS Co-pay Card Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Genentech Access Solutions is your resource for access and reimbursement support services.